Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule with the chemical formula C22H23Cl2N5O2S and a molecular weight of approximately 492.42 Da[1][4][6]. It is classified as an alpha amino acid derivative, but there is no evidence of clinical use, approved indications, or ongoing clinical trials[1][4][7]. The compound has been referenced in structural biology databases (e.g., as ligand "5CB" in the Protein Data Bank), suggesting it may have been used for research purposes such as protein-ligand binding studies[8]. No information on its mechanism of action, pharmacological activity, or therapeutic application is available from current sources.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(5-chloro-benzo[b]thiophen-3-ylmethyl)-2-[6-chloro-oxo-3-(2-pyridin-2-yl-ethylamino)-2H-pyrazin-1-yl]-acetamide.